Why is Windlas Biotech falling/rising?

As of 11-Sep, Windlas Biotech Ltd is currently priced at 997.95, reflecting an increase of 4.35 or 0.44%. The stock's performance today is in line with its sector, although it has shown a decline in investor participation, with delivery volume falling by 48.76% compared to the 5-day average. Despite this drop in participation, the stock has demonstrated strong returns over various periods, including a 1-week increase of 1.27% and a 1-month increase of 6.37%. The company has reported positive financial results, with net sales and profits reaching their highest levels in the latest quarter, contributing to a favorable perception of its valuation despite trading at a premium compared to peers.
In the broader market context, Windlas Biotech's short-term performance has outpaced the Sensex, which has increased by 1.03% over the same week. The stock's year-to-date performance, however, shows a decline of 3.44%, contrasting with the Sensex's gain of 4.36%. This indicates that while the stock has recently gained traction, it has struggled to maintain momentum throughout the year. The company's low debt-to-equity ratio and consistent returns over the past three years further support its stability, but the recent drop in trading volume may suggest caution among investors.